The DOI matches its Crossref record; 92 of the 93 references it cites were found in a registry or an index.
Considerations for determining safety of probiotics: A USP perspective
Open accessAbstract
A history of safe use is a backbone of safety assessments for many current probiotic species, however, there is no global harmonization regarding requirements for establishing probiotic safety for use in foods and supplements. As probiotic manufacturers are increasingly seeking to use new strains, novel species, and next-generation probiotics, justification based on a significant history of use may be challenged. There are efforts underway by a variety of stakeholders, including the United States Pharmacopeia (USP), to develop best practices guidelines for assessing the quality and safety of probiotics. A current initiative of the USP seeks to provide expert advice specific to safety considerations for probiotics. Toward this goal, this review provides a helpful summary guide to global regulatory guidelines. We question the suitability of traditional animal toxicology studies designed for testing chemicals for relevance in assessing probiotic safety. This includes discussion of the use of excessive dose levels, the length of repeated dose toxicity studies needed, and the most suitable animal species used in toxicology studies. In addition, the importance of proper manufacturing practices with regard to final product safety are also included. Thus, an outline of essential parameters of a comprehensive safety assessment for a probiotic are provided.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“To exclude such risks, regulatory authorities (EFSA, FDA) and experts explicitly require strain characterization, phenotypic determination of minimum inhibitory concentration (MIC), and whole genome sequencing (WGS) annotated against carefully curated databases of antibiotic resistance/virulence genes (e.g., CARD, ARG-ANNOT, ResFinder) to determine whether resistance is innate or potentially trans”
From Current Concepts in Probiotic Safety and Efficacy (2026) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This uneven safety assessment weakens the current evidence because probiotic safety cannot be inferred from beneficial functional traits alone and must be supported by strain-level safety evaluation, including assessment of transferable antimicrobial resistance, virulence-associated genes, mobile genetic elements, and toxicological evidence. 42”
From Comparative Genomic Insights into Pangenome Diversity and Functional Adaptation of Akkermansia and Faecalibacterium as Gut-Associated Next-Generation Probiotics: A Systematic Review (2026) · cites this paper as [42]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hill (2014) · doi:10.1038/nrgastro.2014.66 · Cited by 9,592
Self-citationSPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials
Chan, A.-W., Tetzlaff, J. M., Altman, D. G., Laupacis, A., Gøtzsche, P. C., Krleža-Jerić, K., Hróbjartsson, A., Mann, H., Dickersin, K., Berlin, J. A., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-3-201302050-00583 · Cited by 7,363
ResFinder 4.0 for predictions of phenotypes from genotypes
Bortolaia, V., Kaas, R. S., Ruppe, E., Roberts, M. C., Schwarz, S., Cattoir, V., Philippon, A., Allesoe, R. L., Rebelo, A. R., Florensa, A. F., et al. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa345 · Cited by 3,373
Zheng, J., Wittouck, S., Salvetti, E., Franz, C. M. A. P., Harris, H. M. B., Mattarelli, P., O’Toole, P. W., Pot, B., Vandamme, P., Walter, J., et al. (2020) · International Journal of Systematic and Evolutionary Microbiology · doi:10.1099/ijsem.0.004107 · Cited by 3,313
CARD 2020: Antibiotic Resistome Surveillance with the Comprehensive Antibiotic Resistance Database
Alcock, B. P., Raphenya, A. R., Lau, T. T. Y., Tsang, K. K., Bouchard, M., Edalatmand, A., Huynh, W., Nguyen, A.-L. V., Cheng, A. A., Liu, S., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz935 · Cited by 3,202
CARD 2017: expansion and model-centric curation of the comprehensive antibiotic resistance database
Jia, B., Raphenya, A. R., Alcock, B. P., Waglechner, N., Guo, P., Tsang, K. K., Lago, B. A., Dave, B. M., Pereira, S. K., Sharma, A. N., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw1004 · Cited by 2,686
Microbial degradation of complex carbohydrates in the gut
Flint, H. J., Scott, K. P., Duncan, S. H., Louis, P., & Forano, E. (2012) · Gut Microbes · doi:10.4161/gmic.19897 · Cited by 2,331
The Comprehensive Antibiotic Resistance Database
McArthur, A. G., Waglechner, N., Nizam, F., Yan, A., Azad, M. A., Baylay, A. J., Bhullar, K., Canova, M. J., Pascale, G. D., Ejim, L. J., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00419-13 · Cited by 2,287
VFDB 2019: a comparative pathogenomic platform with an interactive web interface
Liu, B., Zheng, D., Jin, Q., Chen, L., & Yang, J. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky1080 · Cited by 1,803
Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement
Ioannidis, J. P. A., Evans, S. J. W., Gøtzsche, P. C., O'Neill, R. T., Altman, D. G., Schulz, K., Moher, D., & for the CONSORT Group* (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00009 · Cited by 1,593
Research works printed but not linked: 3
- Lahtinen, 2009, Safety assessment of probiotics, chapter 31, 1page 1193
- Smith, 2019, Chapter 40: the regulation of probiotics in the United States
- Regulation (EC), 2004, No 853/2004 of the European Parliament and of the Council of 29 April 2004: laying down specific hygiene rules for the hygiene of foodstuffs, J. Eur. Union
Cited by
Sorted by citations
Items 101–137 of 137
Osei, S. A., & Ayisi, C. L. (2024) · Preprints.org · doi:10.20944/preprints202406.1035.v1
Chaudhari, D. N., Ahire, J. J., Kulthe, A. A., & Ghodke, S. V. (2024) · Research Square · doi:10.21203/rs.3.rs-4957452/v1
Patel, M., Kaushik, G., Pandey, S., Ahir, P., Gangurde, N., Mudholkar, N., & Acharya, S. (2025) · Research Square · doi:10.21203/rs.3.rs-7407305/v1
In Vivo Determination of Toxigenicity
Sheth, U. V. (2025) · Methods and protocols in food science · doi:10.1007/978-1-0716-4758-5_21
JATIN, M., ADHIKARI, B., Johnson, A. B., KUMAR, P., & Rajeshkumar, R. (2025) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2025v17i6.54285 · Cited by 1
Roy, D., & Lupien‐Meilleur, J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-24738-5.00007-0
Patel, M., Kaushik, G., Pandey, S., Ahir, P., Gangurde, N., Mudholkar, N., & Acharya, S. (2026) · Comparative Clinical Pathology · doi:10.1007/s00580-026-03816-9
Gregorio, P. R. D., Lieske, I., Nied, C. V., Signori, G., Kuhn, D., Schmitz, C., Martins, V. L. M., Bustamante‐Filho, I. C., Irazoqui, J. M., & de Souza, C. F. V. (2025) · Food Bioscience · doi:10.1016/j.fbio.2025.108066
Shaikh, S. S., Patel, S. S., Patel, P., Malek, F., & Gunjan, V. (2025) · International Journal of Toxicology · doi:10.1177/10915818251407512
In Vivo Determination of Acute and Chronic Toxicity
Stoeva-Grigorova, S. S., Petrova, M. T., & Georgieva, M. P. (2025) · Methods and protocols in food science · doi:10.1007/978-1-0716-4758-5_22
Valero‐Cases, E., Reboredo-González, A., & Frutos, M. J. (2026) · Food Bioscience · doi:10.1016/j.fbio.2026.108314
Probiotics for managing non-alcoholic fatty liver disease: efficacy and mechanistic insights
Ghosh, S., Ghosh, A. J., Adhikari, M. D., Tiwary, B. K., & Saha, T. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-01861-3
A Microbial Odyssey: Reshaping Probiotic Destinies through Advanced Delivery Technologies
Zhang, A., Rong, Y., Gao, Y., Fan, G., Zhao, A., & Qi, S. (2026) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-026-10926-x
Exploring immunoregulatory role of probiotics in cancer-associated cachexia
Mulakhudair, A. R., Shati, Z. R. K., & kh, A. M. (2026) · AIP conference proceedings · doi:10.1063/5.0321872
Sette, N. S. V., Andrade, M. E. R., Trindade, L. M., Borges, A. D., Carneiro, C. C. M., Cardoso, B. G., Fernandes, S. O. A., Gallotti, B., Martins, F. S., Leocádio, P. C. L., et al. (2026) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-026-10964-5
Stanley, C., Ogbonnaya, U. C., Ibezim, C. N. E., & Alex-Wele, M. A. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1014300
Gamma irradiation for producing functional postbiotic ingredients from industrial probiotic biomass
Vitis, V. D., Ferrari, R., Brunelli, L., Minuzzo, M., Biffi, A., Fiore, W., & Guglielmetti, S. (2026) · Food Research International · doi:10.1016/j.foodres.2026.119121
Probiotics and their implications in cancer management
Syed, S. N., Xavier, A., & Rizvi, F. W. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40551-8.00019-6
Habiba, M. U., Rahman, M. M., Augustin, M. A., Varela, C., Morris, H., & Bozkurt, H. (2026) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.70540
How to Apply Microbiome Products for Precision Prevention?
Shin, N., Park, S., Son, W., & Yang, M. (2026) · Food Supplements and Biomaterials for Health · doi:10.52361/fsbh.2026.6.e12
Biotics as targeted microbial alternatives to antibiotics in One Health
Dewan, A. (2026) · Discover Molecules · doi:10.1007/s44345-026-00055-x
Next Generation Probiotics Challenges: A Road to use as Live Bio-Therapeutics
and, H. R., Zaidi, A., & Rashid, H. (2026) · Current Microbiology · doi:10.1007/s00284-026-05044-4 · Cited by 1
Yulianto, A. B., Khairullah, A. R., Lokapirnasari, W. P., Arif, M. A. A., Rosyada, Z. N. A., Sabdoningrum, E. K., Agustono, B., Lamid, M., Purnamasari, K., Pratama, B. P., et al. (2026) · Veterinary World · doi:10.14202/vetworld.2026.3039-3080
Liu, Y., Li, T., Liu, L., Liu, W. T., Ma, X., Wang, Y., Bai, L., & Wang, S. (2026) · Food Control · doi:10.1016/j.foodcont.2026.112499
Lopes, R. B., Okello, E., Tonooka, K. H., Okella, H., Pereira, R. V. V., & Silva-del-Río, N. (2026) · JDS Communications · doi:10.3168/jdsc.2026-1069
Challenges and Considerations in Probiotic Therapy
Raman, M., Mishra, R., Gupta, S. K., Nishtala, S., & Jacob, S. (2026) · Springer eBooks · doi:10.1007/978-981-92-0002-3_21
Metabolic engineering of Candida yeasts for biotechnological applications
Li, X., Wang, Q., Zhang, H.-M., Li, K., & Zhao, X. (2026) · Metabolic Engineering · doi:10.1016/j.ymben.2026.102522
Future directions at the feed-food-health nexus
Elsherbeni, A. I., Swelum, A. A., Ashour, E. A., & El-Hack, M. E. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45446-2.00014-4
Saleena, L. A. K., Soo, M. O. Y., Vijay, D., & Nyam, K. L. (2026) · Journal of Food Science and Technology · doi:10.1007/s13197-026-06859-6
In vitro Safety Assessment of Lactiplantibacillus plantarum HD48 and HD51 Strains for Probiotics Use
Bakeeru, L., Verma, G., Kerketta, J., Kadyan, S., Pandey, B., Pradhan, D., Kapila, S., & Ram, C. (2026) · Journal of Pure and Applied Microbiology · doi:10.22207/jpam.20.3.37
Advances in fermentation and processing technologies for non-dairy probiotic beverages: A review
Panigrahi, S., Gangappa, P., Hema, V., Moses, J. A., Sinija, V. R., & Vidyalakshmi, R. (2026) · Food and Humanity · doi:10.1016/j.foohum.2026.101453
The failure aspects of viable probiotics in foods, supplements, and drugs
Moghadam, S. K., Houshyar, J., Alikhah, H., Keisan, S., & Rad, A. H. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-29835-6.00011-3
Nanoparticles and the gut-microbiome: a dual strategy for oral brain delivery
Negahdari, R., Pouyanfar, N., Masoudifar, R., Aftabi, P., Fendereski, F., Anvari, Z., Masoumi, N., Faizi, M., & Ghorbani‐Bidkorbeh, F. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127477
Akpor, O. B., & Ajinde, A. O. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1953273
Sun, Z., Han, Y., Wang, W., You, L., Wei, C., Yin, S., Jiao, W., Li, S., Ding, Y., & Zhu, Z. (2026) · Food Bioscience · doi:10.1016/j.fbio.2026.110272
Sitdhipol, J., Pengpa, W., Chaiyawan, N., Niwasabutra, K., Bumrungchai, M., Thanagornyothin, T., Kumlung, T., Chaipanya, C., Tanasupawat, S., Phuengjayaem, S., et al. (2026) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-026-11264-8
Metadata
- Authors
- Roe, A. L., Boyte, M.-E., Elkins, C. A., Goldman, V. S., Heimbach, J., Madden, E., Oketch-Rabah, H., Sanders, M. E., Sirois, J., & Smith, A.
- Affiliations
- Procter & Gamble (United States) (US)
- United States Pharmacopeial Convention (US)
- Consumer Healthcare Products Association (US)
- Corresponding author
- Roe, Amy L.
- Venue
- Regulatory Toxicology and Pharmacology
- Publisher
- Elsevier BV
- Published
- 2022-12
- Volume
- 136
- Pages
- 105266
- ISSN
- 0273-2300 (ISSN-L)
- PMC
- PMC10292223
- OpenAlex
- W4300981179
- Cited by
- 136
- References
- 93
- Citations by year
- 2026: 53 · 2025: 45 · 2024: 23 · 2023: 15
- FWCI
- 1.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Regulatory Toxicology and Pharmacology (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nc)
- Funders
- National Institutes of Health (CC999999)
- Topics
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Agricultural and Biological Sciences › Food Science › Agricultural safety and regulations
- Health Sciences › Medicine › Complementary and alternative medicine › Complementary and Alternative Medicine Studies
- Keywords
- probiotics, probiotic safety assessment, regulatory guidelines, United States Pharmacopoeia, veterinary toxicology, repeated-dose toxicity, dose levels, animal species selection, manufacturing practices, international harmonization
- MeSH terms
- Animals, Dietary Supplements, Probiotics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
